Debut is dipping its toes into the contract manufacturing business, with the goal of bringing biotech ingredients to the masses.The new business division harnesses end-to-end services, including novel ingredient discovery, pre-clinical testing, formulation development, quality control production, and access to Debut’s IP portfolio consisting of more than 7,000 proprietary claims.
Britton estimated that the division will generate net revenue of $100 million in the next five years. If approved, Debut can receive a follow-on award of up to $100 million to build a U.S.-based bio-industrial manufacturing facility.
Australia Australia Latest News, Australia Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
These are top biotech stocks to own for the second half of 2024: OppenheimerThese are top biotech stocks to own for the second half of 2024: Oppenheimer
Read more »